Patients With Pancreatic And The Prognosis Of Lung Cancer Patients

1368 Words Jul 8th, 2016 6 Pages
Among patients with pancreatic (1), hepatocellular (2), or breast (3) cancers, comorbidity caused by diabetes mellitus (DM) contributes to diminished long-term survival. Yet, the influence of DM on the prognosis of lung cancer patients remains ambiguous. In lung cancer patients, two studies have shown that patients with DM survived longer than those without (4, 5). In one of these studies (4), the conclusion was based on a small number of patients with unclear diagnostic criteria for DM and inappropriate statistical analyses. In the other study (5), although a larger patient cohort was included, the proportion of lung cancer patients with DM was low (4.5%), and the definition of DM was ambiguous. Also, the survival was very short, regardless of whether the patients had DM. In contrast, past studies indicated that among non-small cell lung cancer (NSCLC) patients, survival was unaffected(6-8) or was decreased by DM (9, 10); and recently, an elevated fasting blood glucose (FBG) level was associated with a significantly higher risk of all-cause mortality in non-small cell lung cancer (NSCLC) patients (11). However, the sample size of those studies was small or not appropriately shown (9-11). Therefore, in this study, we used a strictly defined diagnostic guideline for DM to investigate the prognosis of lung cancer patients with coexisting DM in a large study cohort.

Patients and Methods
All lung cancer patients, admitted between April 1999 and March 2012, to Mito Medical…
Open Document